Evoke Pharma EBITDA 2012-2025 | EVOK
Evoke Pharma ebitda from 2012 to 2025. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
|
Evoke Pharma Annual EBITDA (Millions of US $) |
|
|---|---|
| 2024 | $-5 |
| 2023 | $-7 |
| 2022 | $-8 |
| 2021 | $-8 |
| 2020 | $-13 |
| 2019 | $-7 |
| 2018 | $-8 |
| 2017 | $-11 |
| 2016 | $-11 |
| 2015 | $-12 |
| 2014 | $-13 |
| 2013 | $-3 |
| 2012 | $-2 |
| 2011 | $-2 |
|
Evoke Pharma Quarterly EBITDA (Millions of US $) |
|
|---|---|
| 2025-09-30 | $-1 |
| 2025-06-30 | $-2 |
| 2025-03-31 | $-1 |
| 2024-12-31 | $-1 |
| 2024-09-30 | $-1 |
| 2024-06-30 | $-1 |
| 2024-03-31 | $-2 |
| 2023-12-31 | $-2 |
| 2023-09-30 | $-2 |
| 2023-06-30 | $-2 |
| 2023-03-31 | $-2 |
| 2022-12-31 | $-2 |
| 2022-09-30 | $-2 |
| 2022-06-30 | $-2 |
| 2022-03-31 | $-2 |
| 2021-12-31 | $-2 |
| 2021-09-30 | $-2 |
| 2021-06-30 | $-2 |
| 2021-03-31 | $-3 |
| 2020-12-31 | $-2 |
| 2020-09-30 | $-2 |
| 2020-06-30 | $-7 |
| 2020-03-31 | $-2 |
| 2019-12-31 | $-1 |
| 2019-09-30 | $-2 |
| 2019-06-30 | $-2 |
| 2019-03-31 | $-2 |
| 2018-12-31 | $-2 |
| 2018-09-30 | $-2 |
| 2018-06-30 | $-2 |
| 2018-03-31 | $-2 |
| 2017-12-31 | $-3 |
| 2017-09-30 | $-4 |
| 2017-06-30 | $-3 |
| 2017-03-31 | $-2 |
| 2016-12-31 | $-2 |
| 2016-09-30 | $-2 |
| 2016-06-30 | $-3 |
| 2016-03-31 | $-3 |
| 2015-12-31 | $-3 |
| 2015-09-30 | $-3 |
| 2015-06-30 | $-3 |
| 2015-03-31 | $-3 |
| 2014-12-31 | $-3 |
| 2014-09-30 | $-4 |
| 2014-06-30 | $-3 |
| 2014-03-31 | $-3 |
| 2013-12-31 | $-2 |
| 2013-09-30 | $0 |
| 2013-06-30 | $0 |
| 2013-03-31 | $0 |
| 2012-09-30 | $0 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $0.019B | $0.010B |
| Evoke Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development of drugs to treat gastrointestinal disorders and diseases. The Company's lead product candidate, EVK-001, is in late stage clinical testing which is intended for the treatment of diabetic gastroparesis. Evoke Pharma, Inc. is based in San Diego, California. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $44.899B | 17.67 |
| BridgeBio Pharma (BBIO) | United States | $13.352B | 0.00 |
| Dr Reddy's Laboratories (RDY) | India | $9.749B | 24.85 |
| Aspen Pharmacare (APNHY) | South Africa | $4.248B | 0.00 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.409B | 20.18 |
| Bausch Health Cos (BHC) | Canada | $2.129B | 1.33 |
| Personalis (PSNL) | United States | $1.687B | 0.00 |
| Taysha Gene Therapies (TSHA) | United States | $1.652B | 0.00 |
| Amphastar Pharmaceuticals (AMPH) | United States | $1.019B | 9.58 |
| Assembly Biosciences (ASMB) | United States | $0.519B | 24.98 |
| Sol-Gel Technologies (SLGL) | Israel | $0.178B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.043B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |